Bronchiolitis (RSV): Diagnosis, Severity Triage, and Evidence-Based Management
An AAP-aligned, evidence-based framework for diagnosing acute viral bronchiolitis, triaging severity, delivering supportive care without overuse of bronchodilators or steroids, and integrating modern monoclonal prophylaxis into routine pediatric practice.
Acute viral bronchiolitis is the leading cause of lower-respiratory-tract infection and infant hospitalization worldwide, with respiratory syncytial virus (RSV) responsible for 60–80% of clinically significant cases in children younger than two years. Diagnosis is clinical — viral testing, chest radiography, and routine bloodwork are not required for typical presentations. Management hinges on supportive care: maintenance hydration, gentle nasal suctioning, supplemental oxygen for sustained SpO₂ <90%, and high-flow nasal cannula in moderate-to-severe respiratory failure. Bronchodilators, systemic corticosteroids, antibiotics, and chest physiotherapy are not recommended for routine use. Two paradigm-shifting prophylactic agents have transformed prevention since 2023: nirsevimab — a single intramuscular dose of long-acting monoclonal antibody covering an entire RSV season — and the maternal RSVPreF vaccine administered at 32–36 weeks gestation. Vigilance for apnea is mandatory in infants younger than two months, ex-preterm infants, and those with underlying cardiopulmonary disease.
Pathophysiology and Epidemiology
Bronchiolitis is a clinical syndrome of the lower respiratory tract caused by viral infection of the small airways (bronchioles, <2 mm diameter) in children younger than 24 months. The defining lesion is necrosis of bronchiolar epithelium with submucosal edema, peribronchial mononuclear infiltration, and luminal plugging by sloughed cells, fibrin, and mucus. The infant lung is uniquely susceptible because absolute airway diameter is small, collateral ventilation through pores of Kohn and channels of Lambert is poorly developed, and chest-wall compliance is high — small reductions in airway caliber translate into disproportionate increases in resistance and work of breathing.
Viral etiology
Respiratory syncytial virus (RSV), an enveloped negative-sense single-stranded RNA paramyxovirus with two antigenic subgroups (A and B), accounts for 60–80% of bronchiolitis cases requiring medical attention. Other identified pathogens include rhinovirus (frequently co-detected and associated with later asthma risk), human metapneumovirus, parainfluenza viruses, influenza, adenovirus, coronaviruses (including SARS-CoV-2), and human bocavirus. Viral co-detection occurs in 10–30% of severe cases and is not consistently associated with worse clinical outcome.
Epidemiologic burden
- Universal exposure — virtually all children are infected with RSV by their second birthday
- Seasonality — temperate climates: November through April peak; tropical climates: rainy-season clustering
- Hospitalization — 2–3% of all infants under 12 months in the United States are admitted for RSV bronchiolitis annually; the figure approaches 10% in the lowest socioeconomic quartile
- Global mortality — RSV causes approximately 100,000 deaths in children younger than 5 years worldwide each year, predominantly in low- and middle-income countries
- Long-term consequence — severe RSV bronchiolitis in infancy is associated with a 2- to 3-fold increase in recurrent wheezing through age 5, with biologic vs. genetic causation still debated
Risk factors for severe disease
Severe bronchiolitis is concentrated in identifiable high-risk infants:
- Age — <3 months (especially <6 weeks); apnea risk peaks in <2 months
- Prematurity — gestational age <29 weeks confers 5-fold hospitalization risk
- Chronic lung disease of prematurity (bronchopulmonary dysplasia)
- Hemodynamically significant congenital heart disease
- Neuromuscular disease impairing airway clearance
- Immunocompromise — congenital, oncologic, or post-transplant
- Trisomy 21
- Tobacco smoke exposure and household crowding
Clinical Presentation and Severity Triage
Bronchiolitis follows a stereotyped clinical trajectory: 1–3 days of upper-respiratory prodrome (rhinorrhea, low-grade fever, cough) progressing to lower-respiratory involvement (tachypnea, wheezing, crackles, retractions), peaking at days 3–5, with gradual resolution over 2–3 weeks. Cough may persist for 4 weeks. Fever, when present, is usually low-grade; temperature >39°C should prompt consideration of co-existing bacterial process.
Severity assessment
Severity is determined by a focused bedside assessment integrating respiratory rate, work of breathing, oxygen saturation, mental status, and hydration. No single score is universally adopted; the framework below operationalizes the AAP and NICE 2021 thresholds.
| Parameter | Mild | Moderate | Severe |
|---|---|---|---|
| Respiratory rate | <50/min | 50–70/min | >70/min |
| Retractions | None or mild subcostal | Intercostal + subcostal | Suprasternal + nasal flaring |
| Auscultation | Wheeze ± fine crackles | Wheeze + crackles, fair air entry | Diminished air entry, silent chest |
| SpO₂ (room air) | ≥95% | 90–94% | <90% or sustained drops |
| Feeding | Normal | 50–75% baseline | <50% baseline or refusal |
| Mental status | Alert, playful | Irritable but consolable | Lethargic or inconsolable |
| Apnea | None | None | Witnessed apnea |
Apnea — the silent killer
Apnea may be the presenting feature of bronchiolitis in young infants and can occur without significant respiratory distress. Risk factors include age younger than 2 months, prematurity, and prior apnea. Reported incidence ranges from 5–10% in hospitalized infants under 2 months. All infants younger than 60 days with suspected RSV bronchiolitis warrant cardiopulmonary monitoring during the first 24–48 hours of admission.
Hospitalization criteria
Admit any infant meeting one or more of the following:
- Persistent SpO₂ <90% on room air despite gentle suctioning
- Inability to maintain hydration (oral intake <50% baseline, signs of dehydration)
- Moderate or severe respiratory distress
- Apnea (witnessed or reported)
- Toxic appearance, lethargy, or evidence of impending respiratory failure
- Age <2 months with any moderate clinical feature
- High-risk underlying condition (BPD, hemodynamically significant CHD, immunocompromise)
- Inadequate caregiver capability for home observation, or follow-up not feasible
Diagnosis: Why Less Testing Is More
Bronchiolitis is a clinical diagnosis. The 2014 American Academy of Pediatrics guideline — reaffirmed in subsequent updates and endorsed by the Choosing Wisely campaign — emphasizes that routine viral testing, chest radiography, and laboratory studies are not indicated and may lead to unnecessary intervention.
Diagnostic criteria
- Age <24 months
- Viral upper-respiratory prodrome (rhinorrhea, cough, low-grade fever)
- Lower-respiratory signs: tachypnea, wheeze, crackles, retractions
- First or second wheezing episode (recurrent wheeze in older children suggests asthma instead)
Investigations to avoid in typical disease
| Test | Routine use? | When to consider |
|---|---|---|
| Chest radiograph | No | Atypical course, suspected pneumonia, severe disease, ICU admission, suspected pneumothorax |
| RSV / multiplex viral PCR | No (outpatient) | Cohorting on inpatient ward; immunocompromised host; antiviral candidacy |
| Complete blood count | No | Toxic appearance, suspected secondary bacterial infection |
| Blood culture | No | Concurrent bacteremia suspected (uncommon) |
| Urinalysis / urine culture | Selectively | Febrile infant <60 days even with confirmed RSV — UTI prevalence ≈1–7% |
| Arterial / capillary blood gas | No | Severe disease, impending respiratory failure, ICU monitoring |
Chest radiography of a typical bronchiolitis infant most often shows hyperinflation, peribronchial cuffing, and patchy atelectasis — findings indistinguishable from viral lower-respiratory infection in general and frequently misinterpreted as bacterial pneumonia, leading to inappropriate antibiotic use.
Differential diagnosis
- Asthma exacerbation — recurrent wheeze, atopic history, age >12 months; bronchodilator responsive
- Bacterial pneumonia — focal crackles, high fever, ill appearance, segmental infiltrate
- Foreign body aspiration — sudden onset, asymmetric breath sounds, choking history
- Pertussis — paroxysmal cough, post-tussive emesis, lymphocytosis, age <6 months
- Congestive heart failure — hepatomegaly, gallop rhythm, growth failure, cardiomegaly
- Vascular ring or laryngotracheomalacia — chronic stridor or noisy breathing pre-illness
- Anaphylaxis — temporal trigger, urticaria, multisystem involvement
Treatment: Supportive Care Done Right
The cornerstone of bronchiolitis management is meticulous supportive care. Decades of high-quality evidence have demonstrated that pharmacologic interventions popular in earlier eras — bronchodilators, corticosteroids, antibiotics, chest physiotherapy — provide no meaningful benefit and may cause harm. The clinical instinct to “do something” must be tempered by the discipline to “do nothing pharmacologic” while excelling at the unglamorous fundamentals.
What works — supportive care
- Nasal saline + bulb or wall suction — gentle pre-feed suctioning relieves obstruction in obligate nasal breathers; deep suctioning has not been shown to provide additional benefit and may cause mucosal trauma
- Hydration — small, frequent oral feeds; nasogastric or intravenous fluids if oral intake <50% baseline. Isotonic intravenous fluids (lactated Ringer’s or normal saline) preferred — hypotonic fluids are associated with iatrogenic hyponatremia from SIADH
- Supplemental oxygen — initiate if SpO₂ persistently <90% on room air; titrate to maintain ≥90%. Continuous monitoring should be discontinued once the infant has weaned off oxygen and is feeding well
- High-flow nasal cannula (HFNC) — 2 L/kg/min heated humidified flow with FiO₂ titration. PARIS and PARIS II trials demonstrated reduced treatment failure and need for intubation when HFNC is used as escalation from low-flow oxygen in moderate-to-severe disease. HFNC is not first-line for mild disease
- Nasal CPAP — for HFNC failure or impending respiratory failure; pressure 5–7 cm H₂O
- Mechanical ventilation — for refractory respiratory failure or recurrent apnea; lung-protective settings (VT 6–8 mL/kg, permissive hypercapnia)
What does not work — and may harm
| Intervention | Evidence | Recommendation |
|---|---|---|
| Albuterol / salbutamol | Cochrane 2014: no improvement in admission rate or LOS | Do not routinely administer; brief therapeutic trial discouraged |
| Racemic epinephrine (nebulized) | Cochrane 2017: no benefit in admission rate or LOS in inpatient setting | Do not routinely administer |
| Systemic corticosteroids | Cochrane 2013: no benefit in admission or LOS; no synergy with epinephrine in confirmed studies | Do not administer for first-time bronchiolitis |
| Antibiotics | Bacterial co-infection rate <1% in typical bronchiolitis | Do not administer unless documented or strongly suspected bacterial infection |
| Chest physiotherapy | Cochrane 2016: no benefit; vibration techniques may worsen distress | Do not perform |
| Hypertonic saline (3%) nebulized | Mixed results; potential modest LOS reduction in admissions ≥72h | Optional in inpatients with expected stay >72h; not for ED or short-stay |
| Ribavirin | Modest antiviral activity, expensive, teratogenic to staff | Reserve for severely immunocompromised hosts; not routine |
Prevention: Nirsevimab and Maternal Vaccination
The 2023–2024 RSV season ushered in a new era of immunoprophylaxis with two products that, used together, offer near-comprehensive protection of all infants through their first RSV season: nirsevimab (a long-acting monoclonal antibody) and the maternal RSVPreF vaccine.
Nirsevimab (Beyfortus)
- Mechanism — monoclonal antibody targeting the prefusion conformation of RSV F protein, with YTE Fc modification extending half-life to ~70 days
- Dosing — single intramuscular dose: 50 mg if <5 kg; 100 mg if ≥5 kg
- Eligibility (CDC/AAP 2023) — all infants <8 months entering their first RSV season; high-risk children 8–19 months entering their second season (chronic lung disease of prematurity, severe immunocompromise, cystic fibrosis with severe disease, American Indian/Alaska Native populations)
- Efficacy — MELODY trial: 79.5% reduction in medically attended RSV LRTI through 150 days; HARMONIE: 83.2% reduction in RSV hospitalization
- Timing — administer before or during the RSV season (typically October through March in temperate climates); birth-dose administration during birth hospitalization is preferred for infants born in season
Maternal RSVPreF vaccine (Abrysvo)
- Mechanism — bivalent prefusion F vaccine eliciting transplacental antibody transfer
- Dosing — single intramuscular dose at 32–36 weeks gestation during September through January (Northern Hemisphere)
- Efficacy — MATISSE trial: 81.8% reduction in severe medically attended RSV LRTI in infants through 90 days; 69.4% through 180 days
- Either-or strategy — infants whose mother received maternal RSVPreF vaccine ≥14 days before birth do not generally require nirsevimab
- Safety — no significant signal for preterm birth in the adjusted analysis; recommendation specifically restricts vaccine timing to 32–36 weeks to minimize any theoretical preterm-birth risk
Palivizumab (Synagis) — legacy use
Palivizumab is largely supplanted by nirsevimab in regions where the latter is available. Where palivizumab remains in use (developing countries, supply constraints), AAP eligibility is restricted to high-risk infants:
- Infants born <29 weeks gestation in their first RSV season
- Infants <12 months with chronic lung disease of prematurity (oxygen requirement >21% for ≥28 days after birth)
- Infants <12 months with hemodynamically significant congenital heart disease
Dose: 15 mg/kg IM monthly for up to 5 doses during RSV season. Palivizumab is not effective for treatment of established RSV infection.
Non-pharmacologic prevention
- Hand hygiene — soap-and-water washing or alcohol-based rub before contact with infants
- Environmental tobacco smoke avoidance — strongly counsel against household smoking
- Breastfeeding — exclusive breastfeeding for ≥6 months reduces severe RSV LRTI risk
- Childcare exposure — risk-benefit discussion for high-risk infants during RSV season
- Cohorting — separate RSV-positive inpatients on the ward
Special populations
| Population | Prophylaxis approach |
|---|---|
| Term healthy infant in season | Nirsevimab single dose OR maternal RSVPreF vaccine |
| Preterm <29 wk first season | Nirsevimab; palivizumab if nirsevimab unavailable |
| BPD, on home O₂ | Nirsevimab in first season; second-season nirsevimab if eligible |
| Hemodynamically significant CHD | Nirsevimab; palivizumab post-cardiopulmonary bypass |
| Severe immunocompromise | Nirsevimab; consider extended-season redosing per ID consult |
| Cystic fibrosis (severe phenotype) | Nirsevimab in first season; second season if ongoing severe disease |
Pearls, Pitfalls, and FAQ
Frequently Asked Questions
S7. Practice Insights: Bronchiolitis “Do Less” With Modern Prevention
1. Less Testing Per AAP 2014
In routine practice, the 2014 AAP bronchiolitis guideline (which remains current) explicitly recommends AGAINST routine testing in typical bronchiolitis: do not routinely order chest X-ray (typical findings of hyperinflation + peribronchial thickening don’t change management; CXR risks misinterpretation as pneumonia leading to inappropriate antibiotics), do not routinely order RSV-specific testing (etiology does not change management in typical presentations), do not routinely order CBC or electrolytes in the well-appearing patient. Testing is reserved for atypical presentations, severe disease requiring ICU, immunocompromised host, or concerns for alternative diagnoses (foreign body, congenital heart disease, sepsis). The discipline against unnecessary testing reduces radiation, cost, and inappropriate antibiotic prescribing.
2. Supportive Care Done Right
In experienced hands, supportive care is the ONLY evidence-based treatment for bronchiolitis. The interventions that work: nasal suctioning (gentle, before feeds and sleep — DO NOT do aggressive deep suctioning which causes mucosal trauma), maintenance hydration (PO if tolerated, IV or NG if not — small frequent feeds work better than large boluses in respiratory distress), supplemental oxygen if persistent SpO2 less than 90-92% per AAP. Interventions that DO NOT work and should be avoided: nebulized albuterol (no benefit, may cause tachycardia), nebulized racemic epinephrine (no benefit), nebulized hypertonic saline (mixed evidence, AAP “may be considered” for inpatients but not in ED), systemic corticosteroids (clear no benefit, harm in some studies), antibiotics (only if concurrent bacterial infection, which is rare without otitis media).
3. Respiratory Support Escalation
In routine practice, the respiratory support escalation pathway for moderate-severe bronchiolitis follows: standard nasal cannula low-flow (less than 2 L/min) for mild hypoxemia; high-flow nasal cannula (HFNC) at 1-2 L/kg/min for moderate respiratory distress (signs: nasal flaring, intercostal retractions, persistent tachypnea, SpO2 less than 90% on low-flow); non-invasive ventilation (CPAP 5-7 cmH2O) for failure of HFNC, especially in young infants with apneic episodes; intubation for failure to maintain oxygenation, severe respiratory failure, or apnea. HFNC has substantially reduced intubation rates in moderate bronchiolitis. clinicians avoid bronchodilators throughout — they don’t add benefit and they distract teams from the actual supportive care that matters.
4. Nirsevimab and Maternal Abrysvo
The 2023 introduction of nirsevimab (Beyfortus) is the most important advance in RSV prevention in decades. In experienced practice, every infant entering their first RSV season (or born during RSV season) is offered nirsevimab: single intramuscular dose, 50 mg for less than 5 kg, 100 mg for 5 kg or more, provides protection through the entire RSV season (typically 5+ months of efficacy). Trial data show 70-80% reduction in medically attended RSV LRTI and ~80% reduction in hospitalization. Maternal vaccination with Abrysvo (bivalent RSVpreF) at 32-36 weeks gestation during RSV season is the alternative — provides passive immunity to the infant for the first months of life; either maternal vaccination OR infant nirsevimab is appropriate but generally not both. clinicians document either intervention prominently to avoid double-dosing.
Illustrative Scenario: Severe Bronchiolitis Managed Without Bronchodilators
A 4-month-old previously healthy infant presented in November with 3 days of cough, congestion, fever 38.7°C, poor feeding, and increased work of breathing. Exam: HR 168, RR 64, SpO2 88% on room air, intercostal and subcostal retractions, diffuse wheezes and crackles. RSV nasal swab positive in triage. The covering team had ordered CXR (read as “viral pneumonitis”), CBC, electrolytes, and was about to order nebulized albuterol trial.
On specialty consult the plan was redirected: no need for further CXR or labs given the typical presentation, no albuterol given lack of evidence, focused supportive care. Started HFNC at 6 L/min (~1.5 L/kg/min for ~4 kg infant) with FiO2 0.30, NG feeds at 2/3 maintenance to avoid aspiration risk, gentle nasal suctioning before feeds. Within 2 hours SpO2 was sustained 95%, RR dropped to 48, retractions decreased. Continued HFNC for 36 hours then weaned to room air over 12 hours. Discharged home day 4 without bronchodilators, antibiotics, or steroids — the standard evidence-based path. Family received nirsevimab counseling for next RSV season for the older sibling.
Protocol Refinements vs Standard Approach
- Less testing per AAP 2014: no routine CXR, RSV PCR, CBC, electrolytes in typical bronchiolitis. Reserve for atypical, severe, immunocompromised, or alternative diagnosis concerns.
- Supportive care done right: nasal suctioning (gentle, pre-feed), hydration (small frequent or NG/IV), O2 if SpO2 < 90-92%. Avoid albuterol, epinephrine, steroids, antibiotics.
- Respiratory escalation: low-flow NC → HFNC 1-2 L/kg/min → CPAP 5-7 → intubation. HFNC substantially reduces intubation rates.
- Nirsevimab in first RSV season (50 mg <5 kg / 100 mg ≥5 kg single IM); OR maternal Abrysvo at 32-36 wk in RSV season. Document choice prominently to avoid double-dosing.
- Croup (Laryngotracheobronchitis): Diagnosis, Severity Assessment, and Emergency Management
- Apnea of Prematurity: Diagnosis, Caffeine Therapy, and Discharge Planning
- Pediatric Intussusception: Diagnosis, Reduction, and Surgical Indications
- Reye Syndrome: Aspirin–Viral Illness Association, Mitochondrial Pathophysiology, and ICU Management
- Scarlet Fever: Diagnosis, Penicillin Treatment, and Complications
- Classic Galactosemia: Newborn Screening, Acute Management, and Long-Term Care